ACTION OF SIMVASTATIN IN IMPROVING COGNITIVE FUNCTIONS IN VASCULAR DEMENTIA.

The purpose of this study was to determine the efficacy and safety of statins in improving cognitive function in patients with vascular dementia. As the most important etiological factors of the disease are atherosclerotic vascular lesions, one of the important areas of treatment is lipid metabolism analysis and drug treatment for dyslipidemia. 31 patients were selected for the study, ages 65-65 years, 18 males, 13 females. Twenty patients were included in the study group, treated with Simvastatin (80 mg daily dose). 11 patients were included in the control group. They received placebo therapy. Patients were examined every 4 weeks for 12 weeks using a neuropsychological test with mini-mental scaling, and both groups had low-density lipoprotein and cholesterol levels before and after treatment. In the 12-week post-treatment group, low-density lipoprotein levels were reduced by 54% and cholesterol by 48%. Neuropsychological status examination revealed deterioration of cognitive functions and no difference was observed between study and control group data. Based on the data obtained from our study, it should be noted that correction of lipid metabolism by statins in patients with vascular dementia did not lead to a reduction in cognitive impairment and clinical improvement in patients with vascular dementia.